Publications

Found 103 results
Filters: First Letter Of Last Name is V  [Clear All Filters]
2020
Venturutti L, Teater M, Zhai A, Chadburn A, Babiker L, Kim D, Béguelin W, Lee TC, Kim Y, Chin CR et al..  2020.  TBL1XR1 Mutations Drive Extranodal Lymphoma by Inducing a Pro-tumorigenic Memory Fate.. Cell. 182(2):297-316.e27.
Dooley BJ, Verma A, Ding R, Yang H, Muthukumar T, Lubetzky M, Shankaranarayanan D, Elemento O, Suthanthiran M.  2020.  Urinary Cell Transcriptome Profiling and Identification of ITM2A, SLAMF6, and IKZF3 as Biomarkers of Acute Rejection in Human Kidney Allografts.. Transplant Direct. 6(8):e588.
Verma A, Muthukumar T, Yang H, Lubetzky M, Cassidy MF, Lee JR, Dadhania DM, Snopkowski C, Shankaranarayanan D, Salvatore SP et al..  2020.  Urinary cell transcriptomics and acute rejection in human kidney allografts.. JCI Insight. 5(4)
2019
Glynn S, Lipkin S, Zhang T, Sboner A, Elemento O, van Besien K, Beltran H.  2019.  The application of precision medicine in diagnosing familial Mediterranean fever.. Leuk Lymphoma. 60(8):2091-2093.
Vikova V, Jourdan M, Robert N, Requirand G, Boireau S, Bruyer A, Vincent L, Cartron G, Klein B, Elemento O et al..  2019.  Comprehensive characterization of the mutational landscape in multiple myeloma cell lines reveals potential drivers and pathways associated with tumor progression and drug resistance.. Theranostics. 9(2):540-553.
Vikova V, Jourdan M, Robert N, Requirand G, Boireau S, Bruyer A, Vincent L, Cartron G, Klein B, Elemento O et al..  2019.  Comprehensive characterization of the mutational landscape in multiple myeloma cell lines reveals potential drivers and pathways associated with tumor progression and drug resistance.. Theranostics. 9(2):540-553.
Puca L, Gavyert K, Sailer V, Conteduca V, Dardenne E, Sigouros M, Isse K, Kearney M, Vosoughi A, Fernandez L et al..  2019.  Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer.. Sci Transl Med. 11(484)
Choi S, Wang D, Chen X, Tang LH, Verma A, Chen Z, Kim BJung, Selesner L, Robzyk K, Zhang G et al..  2019.  Function and clinical relevance of RHAMM isoforms in pancreatic tumor progression.. Mol Cancer. 18(1):92.
Chen HJoyce, Poran A, Unni AM, Huang SXuelian, Elemento O, Snoeck H-W, Varmus H.  2019.  Generation of pulmonary neuroendocrine cells and SCLC-like tumors from human embryonic stem cells.. J Exp Med. 216(3):674-687.
Sailer V, Eng KWa, Zhang T, Bareja R, Pisapia DJ, Sigaras A, Bhinder B, Romanel A, Wilkes D, Sticca E et al..  2019.  Integrative Molecular Analysis of Patients With Advanced and Metastatic Cancer.. JCO Precis Oncol. 3
Sailer V, Eng KWa, Zhang T, Bareja R, Pisapia DJ, Sigaras A, Bhinder B, Romanel A, Wilkes D, Sticca E et al..  2019.  Integrative Molecular Analysis of Patients With Advanced and Metastatic Cancer.. JCO Precis Oncol. 3
Mueller FB, Yang H, Lubetzky M, Verma A, Lee JR, Dadhania DM, Xiang JZ, Salvatore SP, Seshan SV, Sharma VK et al..  2019.  Landscape of innate immune system transcriptome and acute T cell-mediated rejection of human kidney allografts.. JCI Insight. 4(13)
Agirre X, Meydan C, Jiang Y, Garate L, Doane AS, Li Z, Verma A, Paiva B, Martín-Subero JI, Elemento O et al..  2019.  Long non-coding RNAs discriminate the stages and gene regulatory states of human humoral immune response.. Nat Commun. 10(1):821.
Springer NL, Iyengar NM, Bareja R, Verma A, Jochelson MS, Giri DD, Zhou XK, Elemento O, Dannenberg AJ, Fischbach C.  2019.  Obesity-Associated Extracellular Matrix Remodeling Promotes a Macrophage Phenotype Similar to Tumor-Associated Macrophages.. Am J Pathol. 189(10):2019-2035.
Karass M, Bareja R, Shelkey E, Vlachostergios PJ, Robinson BD, Khani F, Mosquera JMiguel, Scherr DS, Sboner A, Tagawa ST et al..  2019.  Oncogenic Addiction to ERBB2 Signaling Predicts Response to Trastuzumab in Urothelial Cancer.. J Natl Compr Canc Netw. 17(3):194-200.
Lue JK, Prabhu SA, Liu Y, Gonzalez Y, Verma A, Mundi PS, Abshiru N, Camarillo JM, Mehta S, Chen EI et al..  2019.  Precision Targeting with EZH2 and HDAC Inhibitors in Epigenetically Dysregulated Lymphomas.. Clin Cancer Res. 25(17):5271-5283.
Bhardwaj P, Ikeda T, Zhou XKathy, Wang H, Zheng XEmily, Giri DD, Elemento O, Verma A, Miyazawa M, Mukherjee S et al..  2019.  Supplemental estrogen and caloric restriction reduce obesity-induced periprostatic white adipose inflammation in mice.. Carcinogenesis. 40(7):914-923.
Gambi G, Di Simone E, Basso V, Ricci L, Wang R, Verma A, Elemento O, Ponzoni M, Inghirami G, Icardi L et al..  2019.  The Transcriptional Regulator Sin3A Contributes to the Oncogenic Potential of STAT3.. Cancer Res. 79(12):3076-3087.
Finnerty BM, Moore MD, Verma A, Aronova A, Huang S, Edwards DP, Chen Z, Seandel M, Scognamiglio T, Du Y-CNancy et al..  2019.  UCHL1 loss alters the cell-cycle in metastatic pancreatic neuroendocrine tumors.. Endocr Relat Cancer. 26(4):411-423.
Robinson BD, Vlachostergios PJ, Bhinder B, Liu W, Li K, Moss TJ, Bareja R, Park K, Tavassoli P, Cyrta J et al..  2019.  Upper tract urothelial carcinoma has a luminal-papillary T-cell depleted contexture and activated FGFR3 signaling.. Nat Commun. 10(1):2977.
2018
González-González A, Muñoz-Muela E, Marchal JA, Cara FE, Molina MP, Cruz-Lozano M, Jiménez G, Verma A, Ramírez A, Qian W et al..  2018.  Activating Transcription Factor 4 Modulates TGFβ-Induced Aggressiveness in Triple-Negative Breast Cancer via SMAD2/3/4 and mTORC2 Signaling.. Clin Cancer Res. 24(22):5697-5709.
Verma N, Pan H, Doré LC, Shukla A, Li QV, Pelham-Webb B, Teijeiro V, González F, Krivtsov A, Chang C-J et al..  2018.  Author Correction: TET proteins safeguard bivalent promoters from de novo methylation in human embryonic stem cells.. Nat Genet. 50(5):764.
Li W, Xia S, Aronova A, Min IM, Verma A, Scognamiglio T, Gray KD, Ullmann TM, Liang H, Moore MD et al..  2018.  CHL1 expression differentiates Hürthle cell carcinoma from benign Hürthle cell nodules.. J Surg Oncol. 118(6):1042-1049.
Bakhoum SF, Ngo B, Laughney AM, Cavallo J-A, Murphy CJ, Ly P, Shah P, Sriram RK, Watkins TBK, Taunk NK et al..  2018.  Chromosomal instability drives metastasis through a cytosolic DNA response.. Nature. 553(7689):467-472.
Faria M, Karami S, Granados-Principal S, Dey P, Verma A, Choi DS, Elemento O, Bawa-Khalfe T, Chang JC, Strom AM et al..  2018.  The ERβ4 variant induces transformation of the normal breast mammary epithelial cell line MCF-10A; the ERβ variants ERβ2 and ERβ5 increase aggressiveness of TNBC by regulation of hypoxic signaling.. Oncotarget. 9(15):12201-12211.